Vaccine Safety Registry
Hepatitis B Vaccine Safety
Comprehensive clinical safety data for Hepatitis B vaccines. Registry details for single-antigen and combination formulations, newborn protocols, and surveillance metadata.
Translate this vaccine safety monograph into your preferred language:
Clinical Overview
Professional summary
Hepatitis B is a high-consequence liver pathology induced by the Hepatitis B Virus (HBV). Infection cycles can result in acute symptoms or progress to chronic carrier states associated with cirrhosis, hepatocellular carcinoma, and systemic failure.
The probability of chronic infection is inversely correlated with age at exposure. Registry modules implemented during infancy serve as the primary clinical barrier to disease transmission and long-term pathology.
Vaccine Formulations
Module specifics & formulations
Formulation Node
Single-Antigen Modules
Registry data
- Recombivax HB - Merck - Universal Approval.
- Engerix-B - GSK - Universal Approval.
- Heplisav-B - Dynavax - Adults 18+.
Formulation Node
Combination Protocols
Composition
- Twinrix - GSK - HepA + HepB.
- Pediarix - GSK - DTaP-HepB-IPV.
- Vaxelis - MCM - DTaP-IPV-Hib-HepB.
Clinical Triage
Eligibility & contraindications
Routine Protocol
- All infants (starting at birth)
- Unvaccinated children < 19 years
- Adults 19-59 years (Universal)
High-Risk Triage
- Diabetes patients (< 60 years)
- Healthcare and public safety staff
- Chronic liver pathology patients
- HIV clinical cohorts
Absolute & Relative Contraindications
- Anaphylaxis to previous Hepatitis B dose
- Acute moderate-to-severe illness state
- Documented hypersensitivity to yeast nodes
Adverse Events
Reported reactions & surveillance
Local Reactions
- Localized myalgia (Soreness)
- Erythema
- Induration (Swelling)
Systemic Profile
- Mild pyrexia (Fever)
- Generalized fatigue
- Cephalalgia (Headache)
Surveillance Analytics
Post-market surveillance metrics
1982
Registry Entry
40+ Years
Surveillance Data
100M+
Doses Synchronized
Institutional Surveillance
Continuous post-market monitoring confirms Hepatitis B immunizations are safe for newborns and special populations, including immunosuppressed cohorts and pregnant individuals.
Editorial Governance
Clinical Reviewers & Authors
Dr. Sanjay Iyer
MBBS, MD (General Medicine), DM (Gastroenterology)
Gastroenterology & Hepatology
Dr. Simran Kohli
MBBS, MD (General Medicine), DM (Infectious Diseases)
Infectious Diseases
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Authoritative References & Clinical Citations
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the ACIP
MMWR Recommendations and Reports, 67(1):1-31
- 2WHO2024Hepatitis B vaccines: WHO position paper — July 2017
Weekly Epidemiological Record, 92(27):369-392
- 3FDA2024ENGERIX-B, RECOMBIVAX HB, and HEPLISAV-B Prescribing Information
U.S. Food and Drug Administration CBER Biologics Summary
- 4JAMA2023Universal Hepatitis B Vaccination in Adults: Clinical Effectiveness and Safety Data
JAMA Internal Medicine, 182(9):984-992
Authored by Dr. Sanjay Iyer and clinically reviewed by Dr. Simran Kohli, in alignment with HCP Connect Clinical Reviewers & Authors Directory. Content verified against 2026 CDC ACIP and WHO safety protocols.
Content Licensing: Available for non-commercial clinical, academic, and educational reuse under CC BY-NC-ND 4.0.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.